Research Analysts Set Expectations for TCRX Q3 Earnings

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Equities research analysts at Lifesci Capital issued their Q3 2025 earnings per share estimates for TScan Therapeutics in a report released on Thursday, August 14th. Lifesci Capital analyst S. Slutsky anticipates that the company will earn ($0.31) per share for the quarter. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.12) per share. Lifesci Capital also issued estimates for TScan Therapeutics’ Q4 2025 earnings at ($0.31) EPS.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.28) EPS for the quarter, hitting analysts’ consensus estimates of ($0.28). TScan Therapeutics had a negative return on equity of 63.33% and a negative net margin of 1,964.88%. The firm had revenue of $3.08 million for the quarter, compared to the consensus estimate of $1.31 million.

TCRX has been the subject of a number of other research reports. HC Wainwright decreased their target price on TScan Therapeutics from $15.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Wedbush reaffirmed an “outperform” rating and set a $7.00 target price on shares of TScan Therapeutics in a research report on Tuesday. Finally, Wall Street Zen raised TScan Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, July 12th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, TScan Therapeutics has an average rating of “Moderate Buy” and an average price target of $7.80.

TScan Therapeutics Stock Down 0.6%

Shares of TScan Therapeutics stock opened at $1.80 on Friday. The stock has a market capitalization of $101.86 million, a P/E ratio of -1.65 and a beta of 0.99. The company has a quick ratio of 8.55, a current ratio of 7.06 and a debt-to-equity ratio of 0.18. The stock has a 50 day moving average price of $1.67 and a two-hundred day moving average price of $1.67. TScan Therapeutics has a 12-month low of $1.02 and a 12-month high of $6.23.

Institutional Investors Weigh In On TScan Therapeutics

Hedge funds have recently modified their holdings of the business. Catalyst Funds Management Pty Ltd bought a new stake in shares of TScan Therapeutics in the second quarter valued at approximately $26,000. Vanguard Personalized Indexing Management LLC bought a new position in TScan Therapeutics in the second quarter worth $29,000. Quadrature Capital Ltd bought a new position in TScan Therapeutics in the second quarter worth $33,000. Boothbay Fund Management LLC lifted its position in TScan Therapeutics by 50.0% in the second quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock worth $35,000 after purchasing an additional 8,121 shares during the period. Finally, ProShare Advisors LLC bought a new position in TScan Therapeutics in the fourth quarter worth $40,000. 82.83% of the stock is owned by institutional investors.

Insider Buying and Selling at TScan Therapeutics

In other TScan Therapeutics news, major shareholder Lynx1 Capital Management Lp acquired 1,200,000 shares of TScan Therapeutics stock in a transaction dated Tuesday, May 20th. The stock was bought at an average cost of $1.20 per share, with a total value of $1,440,000.00. Following the completion of the transaction, the insider owned 7,946,141 shares of the company’s stock, valued at $9,535,369.20. The trade was a 17.79% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 4.35% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.